A wealth of evidence has led to the conclusion that virtually all cases of cervical cancer are attributable to persistent infection by a sub-set of HPV types, especially HPV16 and HPV18. These HPVs also cause a proportion of other cancers, including vulvar, vaginal, anal, penile, and oropharyngeal cancers. Although cervical cancer screening, primarily via the Pap smear, has reduced the incidence of this cancer in industrialized countries, cervical cancer remains the second most common cause of death from cancer in women worldwide, as the developing world has lacked the resources for widespread high quality screening. In addition to advances in Pap smear technology, identification of HPV as the etiologic agent has produced two recent advances that may have a major impact on approaches to reduce the incidence of this disease. The first is development of a preventive vaccine whose current versions appear to prevent close to 100% of persistent genital infection and disease caused by HPV16 and HPV18; future second generation vaccines may be able to protect against oncogenic infections by a broader array of HPV types. The second is the incorporation of HPV testing into screening programs. In women over 30, HPV testing can identify high grade dysplasias earlier than Pap smears, with acceptable rates of specificity. These results, together with the high sensitivity of HPV testing, imply that such testing could permit increased intervals for screening. An inexpensive HPV test in development might, if successful, be incorporated as part of an economically viable “screen-and-treat” approach in the developing world. The manner in which vaccination and screening programs are integrated will need to be carefully considered, so they can efficiently reduce the overall incidence of cervical cancer.